Circulating Lp-PLA2 is associated with high valvuloarterial impedance and low arterial compliance in patients with aortic valve bioprostheses

Clinica Chimica Acta; International Journal of Clinical Chemistry
Ablajan MahmutPatrick Mathieu

Abstract

We previously reported that plasma Lp-PLA2 was associated with aortic valve disease progression and degeneration of bioprostheses. Low systemic arterial compliance and high valvuloarterial impedance (Z(va)) are predictors of poor survival in patients with aortic valve disease. However, the prevalence of high Z(va) after AVR is largely unknown and whether Lp-PLA2 could predict Z(va) has not been documented. We investigated the relationships between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity and valvuloarterial impedance (Z(va)), an index of global LV hemodynamic load, in patients that underwent aortic valve replacement (AVR). A total of 195 patients with aortic bioprostheses underwent echocardiographic assessment of the prosthetic aortic valve function 8±3.4 years after AVR. Lp-PLA2 mass and activity were measured. In this group of patients, the mean Z(va) was elevated (5.73±1.21 mm Hg·ml(-1)·m(2)). In univariate analyses, Lp-PLA2 mass (p=0.003) and Lp-PLA2 activity (p=0.046) were associated with Z(va). After adjustment for covariates including age, gender, clinical risk factors, anti-hypertensive medications, body mass index and prosthesis size, Lp-PLA2 mass was associated with high Z(va) (≥4.5 m...Continue Reading

Associated Clinical Trials

References

Sep 22, 2001·Hypertension·C U ChaeP M Ridker
Jul 29, 2006·The Journal of Thoracic and Cardiovascular Surgery·Siamak MohammadiFrançois Dagenais
Aug 11, 2007·International Journal of Cardiology·Sing-Chien YapJolien W Roos-Hesselink
Jun 6, 2009·European Journal of Clinical Investigation·R ShettyP Mathieu
Sep 5, 2009·Journal of the American College of Cardiology·Zeineb HachichaPhilippe Pibarot
Feb 16, 2010·Biochimie·Sonia-Athina KarabinaEwa Ninio
Feb 8, 2013·The New England Journal of Medicine·George ThanassoulisUNKNOWN CHARGE Extracoronary Calcium Working Group
Oct 29, 2013·Journal of the American College of Cardiology·Pia R KamstrupBørge G Nordestgaard
Dec 18, 2013·European Journal of Clinical Investigation·Ablajan MahmutPatrick Mathieu
Mar 22, 2014·JACC. Cardiovascular Imaging·Jeanette Schulz-Menger
Apr 15, 2014·JACC. Cardiovascular Imaging·Tor Biering-SørensenHanne Christensen
Apr 17, 2014·Nature Reviews. Cardiology·Alexandra Roberts
Aug 3, 2014·The Canadian Journal of Cardiology·Patrick Mathieu, Marie-Chloé Boulanger

❮ Previous
Next ❯

Citations

Feb 4, 2021·JACC. Basic to Translational Science·Rihab BoucharebDjamel Lebeche

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.